US Patent

US9290504 — 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors

Composition of Matter · Assigned to Merck Sharp and Dohme BV · Expires 2032-07-11 · 6y remaining

Vulnerability score 4/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects 6-5 membered fused pyridine ring compounds according to formula (I) or a pharmaceutically acceptable salt thereof.

USPTO Abstract

The present invention relates to 6-5 membered fused pyridine ring compounds according to formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to formula I in the treatment of Brutons Tyrosine Kinase (Btk) mediated disorders.

Drugs covered by this patent

Patent Metadata

Patent number
US9290504
Jurisdiction
US
Classification
Composition of Matter
Expires
2032-07-11
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Merck Sharp and Dohme BV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.